Mediterranean Journal of Hematology and Infectious Diseases最新文献_第4页

Heparin-binding Protein as a Diagnostic and Prognostic Marker of Infections: A Systematic Review and Meta-analysis. 肝素结合蛋白作为感染的诊断和预后指标：一项系统综述和荟萃分析。

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.029

Wanchun Yang, Wei Dong

{"title":"Heparin-binding Protein as a Diagnostic and Prognostic Marker of Infections: A Systematic Review and Meta-analysis.","authors":"Wanchun Yang, Wei Dong","doi":"10.4084/MJHID.2025.029","DOIUrl":"https://doi.org/10.4084/MJHID.2025.029","url":null,"abstract":"Heparin-binding protein (HBP) is a granule protein derived from neutrophils, located in secretory vesicles and neutrophilic granules, also known as cationic antimicrobial protein of 37 kDa (CAP37) or azurocidin. This study evaluates the diagnostic and prognostic value of HBP levels in relation to infection, organ dysfunction, and mortality in adult patients. A systematic review and meta-analysis were conducted by searching PubMed, Web of Science, EMBASE, and the Cochrane Database from their inception through June 2024. Original studies assessing HBP levels' diagnostic and prognostic utility in predicting infection and disease severity in critically ill adult patients were included. The primary outcome was the diagnostic and predictive role of HBP in infection and severity. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was used to evaluate bias risk. A total of 56 studies involving 11,486 patients were included. Pooled analysis showed HBP had a sensitivity of 0.87 (95% CI, 0.82-0.91), specificity of 0.87 (95% CI, 0.79-0.92), and an AUC of 0.93 (95% CI, 0.91-0.95) for infection diagnosis. For prognostic assessment, sensitivity was 0.77 (95% CI, 0.74-0.80), specificity was 0.72 (95% CI, 0.68-0.76), and AUC was 0.81 (95% CI, 0.78-0.85). HBP outperformed procalcitonin (PCT), C-reactive protein (CRP), and white blood cell count (WBC) in diagnosing and predicting critical illness. No publication bias was detected. HBP demonstrates high sensitivity and specificity for diagnosing infections in critically ill adult patients. Additionally, it effectively predicts disease progression, including organ dysfunction and mortality, surpassing traditional biomarkers such as PCT, CRP, and WBC. All that cannot be true for subjects with severe neutropenia.","PeriodicalId":18498,"journal":{"name":"Mediterranean Journal of Hematology and Infectious Diseases","volume":"17 1","pages":"e2025029"},"PeriodicalIF":2.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicities Associated with CAR-T Cell Therapies. 与CAR-T细胞疗法相关的毒性

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.039

Ugo Testa, Germana Castelli, Elvira Pelosi, Eugenio Galli, Patrizia Chiusolo

引用次数: 0

Early Use of Thrombopietin Receptor Agonists (Tpo-Ras) in Clinical Practice: Results from an Italian Survey on Behalf of the Gimema Working Group Anemia and Thrombocytopenia. 血小板生成素受体激动剂（Tpo-Ras）在临床实践中的早期使用：来自意大利贫血和血小板减少症Gimema工作组调查的结果。

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.041

Mariasanta Napolitano, E Lucchini, M R De Paolis, A Urso, A Lucchesi, N Vianelli, F Zaja, C Santoro

引用次数: 0

Plasmodium vivax Infections in Duffy-Negative Individuals: A Paradigm Shift in Indian Malaria Epidemiology. 间日疟原虫感染达菲阴性个体：印度疟疾流行病学的范式转变。

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.044

Roshan Shaikh, Kanjaksha Ghosh, Ajit Gorakshakar

{"title":"Plasmodium vivax Infections in Duffy-Negative Individuals: A Paradigm Shift in Indian Malaria Epidemiology.","authors":"Roshan Shaikh, Kanjaksha Ghosh, Ajit Gorakshakar","doi":"10.4084/MJHID.2025.044","DOIUrl":"https://doi.org/10.4084/MJHID.2025.044","url":null,"abstract":"Background: To investigate the occurrence of Plasmodium vivax infections in Duffy-negative individuals, challenging the long-held belief that P. vivax requires the Duffy antigen receptor for chemokines to infect human erythrocytes.Materials and methods: In the present study, 365 samples were screened using serological techniques, PCR-RFLP analysis, and DNA sequencing of the ACKR1 gene promoter region mutation to identify Duffy-negative individuals. P. vivax infection was detected using PCR targeting the 18S rRNA gene and microscopic examination of Giemsa-stained blood smears.Results: Five individuals (1.36%) were confirmed Duffy-negative (Fy(a-b-)). Surprisingly, 3 out of these 5 Duffy-negative subjects (60%) were infected with P. vivax, as confirmed by both microscopy and PCR. Various parasite stages were observed in infected Duffy-negative samples, with parasitaemia ranging from 0.01% to 0.5%.Discussion: Our findings provide compelling evidence that P. vivax can infect Duffy-negative individuals, suggesting the existence of alternative invasion pathways or adaptations. This has profound implications for P. vivax biology, evolution, and global distribution. The burden of vivax malaria may be underestimated, particularly in regions with a high prevalence of Duffy negativity. This study highlights the need to reevaluate P. vivax epidemiology, diagnostic approaches, and control strategies, especially in areas previously considered at low risk. Further research is needed to elucidate the mechanisms enabling P. vivax invasion of Duffy-negative erythrocytes and to assess the clinical and epidemiological consequences of these infections.","PeriodicalId":18498,"journal":{"name":"Mediterranean Journal of Hematology and Infectious Diseases","volume":"17 1","pages":"e2025044"},"PeriodicalIF":2.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thalidomide Treatment for Thrombocytopenia Secondary to Hypersplenism in Children with Transfusion-Dependent β-Thalassemia: A Case Series. 沙利度胺治疗输血依赖性β-地中海贫血儿童继发于脾功能亢进的血小板减少症：一个病例系列。

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.037

Xiaoqing Gong, Jian Xiao, Wenqiang Kong, Xiaodong Liu, Kun Yang

引用次数: 0

Addition of Daratumumab to First-Line Therapy of Newly Diagnosed Multiple Myeloma in Patients Eligible for Autologous Stem Cell Transplantation: A Single-Center Real-Life Experience. 在符合自体干细胞移植条件的新诊断多发性骨髓瘤患者的一线治疗中增加Daratumumab：单中心现实经验

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.040

Edoardo Olivari, Laura Paris, Paola Stefanoni, Chiara Pavoni, Alessandro Rambaldi, Monica Galli

引用次数: 0

Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing. 多发性骨髓瘤的双特异性抗体和CAR - T：患者的适当选择和测序。

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.045

M Puppi, I Sacchetti, K Mancuso, P Tacchetti, L Pantani, I Rizzello, M Iezza, M Talarico, E Manzato, S Masci, R Restuccia, S Barbato, S Armuzzi, B Taurisano, I Vigliotta, E Zamagni

{"title":"Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing.","authors":"M Puppi, I Sacchetti, K Mancuso, P Tacchetti, L Pantani, I Rizzello, M Iezza, M Talarico, E Manzato, S Masci, R Restuccia, S Barbato, S Armuzzi, B Taurisano, I Vigliotta, E Zamagni","doi":"10.4084/MJHID.2025.045","DOIUrl":"https://doi.org/10.4084/MJHID.2025.045","url":null,"abstract":"T-cell redirecting therapies (TCR) marked a step forward in the treatment of relapsed/refractory multiple myeloma (RRMM). These agents, represented by chimeric antigen receptor (CAR) T-cells and bispecific antibodies (BsAbs), proved to ameliorate the prognosis of difficult-to-treat patients in pivotal clinical trials, leading to their introduction into clinical practice. Both strategies rely on recruiting patients' T-cells against specific tumor antigens, with B-cell maturation antigen (BCMA) and G-protein coupled receptor group C family 5 member D (GPRC5D) being the targets most extensively studied. Nevertheless, most of these regimens under the current label do not hesitate in a clear plateau of survival curves, thus raising the scenario of patients receiving more than one TCR agent in sequence. Also, they differ in their toxicity profiles and administration features. Consequently, the appropriate application of these agents mandates a careful selection of the right treatment for the right patient, with the ultimate intent of optimizing patient outcomes. In this respect, practical considerations regarding tumor- and patient-specific features are of high importance. Tailored clinical trials and analysis of real-word experiences are also crucial to produce evidence-based recommendations. Likewise, pre-clinical research is critical for the conceptualization of treatment algorithms potentially driven by immunological clues and knowledge of mechanisms of resistance. In this review we aim at providing practical guidance for defining the most appropriate treatment sequencing and determining the selection of patients for each treatment.","PeriodicalId":18498,"journal":{"name":"Mediterranean Journal of Hematology and Infectious Diseases","volume":"17 1","pages":"e2025045"},"PeriodicalIF":2.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isavuconazole Successfully Treated Pulmonary Mucormycosis in Acute Myeloid Leukemia: A Case Report. 依唑康唑成功治疗急性髓系白血病肺毛霉病1例。

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.031

Hong Chen, Kun Chen, Wenqiang Kong

引用次数: 0

Molecular Characterization of Epstein - Barr virus Based on EBNA3C Protein among Hematopoietic Stem Cell Transplant Recipients in Jordan. 基于EBNA3C蛋白的约旦造血干细胞移植受者Epstein - Barr病毒的分子特征

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.032

Rabaa Y Athamneh, Hiba A Swaity, Waleed Al Moman, Hayyan I Al-Taweil, Assia Benbraiek, Anas H Khalifeh

{"title":"Molecular Characterization of Epstein - Barr virus Based on EBNA3C Protein among Hematopoietic Stem Cell Transplant Recipients in Jordan.","authors":"Rabaa Y Athamneh, Hiba A Swaity, Waleed Al Moman, Hayyan I Al-Taweil, Assia Benbraiek, Anas H Khalifeh","doi":"10.4084/MJHID.2025.032","DOIUrl":"https://doi.org/10.4084/MJHID.2025.032","url":null,"abstract":"Background: Epstein-Barr virus (EBV), a human herpes virus, presents significant risks to hematopoietic stem cell transplant (HSCT) recipients due to immunosuppressive treatments. Two genotypes of EBV can infect humans: EBV1 and EBV2. These genotypes differ in their latent genes. One important latent protein is EBNA3, which plays a crucial role in immune evasion and pathogenesis of EBV.Objectives: This study characterizes EBV genotypes among HSCT recipients in Jordan and examines the relationship between EBV positivity and demographic factors.Methods: A retrospective observational study was conducted at the Jordanian Royal Medical Services Hospital (JRMS) from January to October 2024. Blood samples were collected from the virology department, and plasma was separated. EBV-DNA detection was performed using quantitative real-time PCR, while conventional PCR targeted EBNA3C genes for genotyping.Results: Out of 93 EBV-positive HSCT recipients, 31 underwent genotyping analysis. The findings revealed a predominance of EBV2, detected in 26 samples (84%), while 5 samples (16%) exhibited mixed infections. Notably, EBV1 was not identified in any samples. A significant association was found between EBV positivity and male recipients, with a markedly higher prevalence in individuals under 18 years of age (P<0.0001).Conclusion: EBV2 was the predominant genotype among HSCT recipients in Jordan, with coinfections of EBV1 and EBV2. Understanding the prevalent genotypes in transplant patients is crucial for managing EBV-related complications, ultimately improving patient outcomes. This study highlights the need for continuous monitoring and characterization of EBV genotypes in immunocompromised populations.","PeriodicalId":18498,"journal":{"name":"Mediterranean Journal of Hematology and Infectious Diseases","volume":"17 1","pages":"e2025032"},"PeriodicalIF":2.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma. 多发性骨髓瘤抢救治疗的适当测序更新。

IF 2 4区医学

Mediterranean Journal of Hematology and Infectious Diseases Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.4084/MJHID.2025.043

Gregorio Barilà, Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

{"title":"An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.","authors":"Gregorio Barilà, Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello","doi":"10.4084/MJHID.2025.043","DOIUrl":"https://doi.org/10.4084/MJHID.2025.043","url":null,"abstract":"Current treatment strategies have led to unpredictable improvements in the management of multiple myeloma (MM) over time. However, resistance to therapy, particularly regarding lenalidomide refractoriness and, more recently, daratumumab and lenalidomide refractoriness, even in the first-line setting, has become an increasingly significant issue in recent years. This resistance complicates the identification of the optimal treatment algorithm for patients with relapsed/refractory MM, particularly at first relapse. In this review, we focus on current strategies for MM patients progressing on or after lenalidomide-based and daratumumab-lenalidomide-based regimens. The forthcoming availability of next-generation immunotherapies, along with a deeper understanding of resistance mechanisms, is highly anticipated. Meanwhile, based on promising results from recent studies, the approval of novel drugs to expand the current therapeutic armamentarium against MM is bringing us closer to the goal of making a potential cure for the disease much more achievable in the hopefully near future.","PeriodicalId":18498,"journal":{"name":"Mediterranean Journal of Hematology and Infectious Diseases","volume":"17 1","pages":"e2025043"},"PeriodicalIF":2.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0